

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. DLP Marquette General Hospital, LLC d/b/a Marquette General Hospital</p> <p>2. 580 West College Marquette, MI 49855-2705</p>	<p>In accordance with letter dated November 12, 2013,</p> <p>3. License number 21-05432-04 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date July 31, 2014</p> <hr/> <p>5. Docket No. 030-18133 Reference No.</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Cesium-137 as permitted by 10 CFR 35.400</p> <p>E. Iridium-192 as permitted by 10 CFR 35.400</p> <p>F. Yttrium-90 as permitted by 10 CFR 35.1000</p> <p>G. Uranium (depleted in Uranium-235)</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Amersham Model CDC.T1; 3M Health Physics Model Series 6501 - 6503, inclusive; and Isotope Products Laboratories Model 67-6500 Series)</p> <p>E. Sealed sources (Best Medical International, Inc., Model 81-01)</p> <p>F. Sealed Sources (SIR-Spheres (AEA Technology QSA, Inc.))</p> <p>G. Solid Metal</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 9 curies</p> <p>D. 1400 millicuries</p> <p>E. 600 millicuries</p> <p>F. 1.08 curies</p> <p>G. 999 kilograms</p>
---	--	---

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-05432-04

Docket or Reference Number
030-18133

Amendment No. 69
Corrected Copy

- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- F. For medical use, as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.
- G. Shielding in generators.

CONDITIONS

10. Locations of Use: 420 W. Magnetic Street, Marquette, Michigan, and 580 W. College Avenue, Marquette, Michigan.
11. Radiation Safety Officer: Julia M. (Shan) Marlette, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

John Michael Pap, M.D.

Paul O. Thieme, Jr., D.O.

Raymond Wood, D.O.

Christopher J. Mehall, M.D.

Nelson E. Gencheff, D.O.

Gary M. Friesen, M.D.

Michael Ouimette, M.D.

Kevin Scott Gostenik, M.D.

Material and Use

10 CFR 35.100 and 35.200.

10 CFR 35.300, 35.400, and **35.1000, limited to** yttrium-90 SIR-spheres in a Sirtex Medical Limited brachytherapy afterloader delivery system.

10 CFR 35.200.

10 CFR 35.100, 35.200, 35.300, and **35.1000, limited to** yttrium-90 SIR-spheres in a Sirtex Medical Limited brachytherapy afterloader delivery system.

10 CFR 35.200.

10 CFR 35.200.

10 CFR 35.100, 35.200, 35.300, and **35.1000, limited to** yttrium-90 SIR-spheres in a Sirtex Medical Limited brachytherapy afterloader delivery system.

10 CFR 35.100, 35.200, and 35.300, limited to oral administration of sodium iodide iodine-131.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-05432-04Docket or Reference Number
030-18133Amendment No. 69
Corrected Copy

13. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 30, 2003; and
- B. Letters dated December 30, 2003, July 1, 2004, April 11, 2005, May 25, 2005, August 12, 2009 (with attachments), February 23, 2010 (with attachments), May 11, 2010, September 20, 2012, December 12, 2012, and February 20, 2013.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JAN 22 2014

By

Toye L. Simmons
Materials Licensing Branch
Region III